Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
Opinions John Stephenson
Shire PLCSHPGTOP PICKApr 18, 2017
John StephensonOwned
$169.64
Stock price when the opinion was issued
biotechnologypharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
You might be interested:
PAST TOP PICK
(A Top Pick Feb 1/12. Up 2.18%.) Focused on special opportunities in the pharmaceutical world. Got under pressure because there were generics coming in on their key drugs but it turned out the risk wasn’t as threatening as the market had expected. Stock has been rallying lately.
Ian AinsworthOwned
biotechnologypharmaceutical
TOP PICK
Irish pharmaceutical company and its major franchise is Adderall for attention deficit disorder. The opportunity here is that they can move it into adults. The other part of their business is orphan drugs, drugs that are not targets for large pharmaceuticals.
Ian AinsworthOwned
biotechnologypharmaceutical
TOP PICK
A UK company that does such nervous system pharmaceutical products. The big product is for hyperactive disorder. Adderall, a big seller, does not become generic for three years. Multiple in the high teens. Also has five new products coming out.
Ian AinsworthOwned
biotechnologypharmaceutical
A pharmaceutical/biotech company. It has an extremely attractive valuation, dirt cheap, trading at under 11X forward earnings. This has a really good stable of rare disease drugs that are very much untouched in the marketplace. The pharmaceutical sector has been absolutely beaten up and is becoming absolutely compelling. Dividend yield of 0.53%. (Analysts’ price target is £6100.)